{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.4","upperLimit":"56.8","value":"44.3"},{"groupId":"OG001","lowerLimit":"23.3","upperLimit":"38.6","value":"29.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"261"},{"groupId":"OG001","value":"257"}],"units":"Participants"}],"description":"The time from registration to disease progression or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)","id":"OG000","title":"Arm A"},{"description":"AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)","id":"OG001","title":"Arm B"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"7 years 3 months","title":"Progression-free Survival (PFS) as Assessed by Investigator","type":"PRIMARY","unitOfMeasure":"months"}